Form 8-K - Current report:
SEC Accession No. 0001140361-25-002125
Filing Date
2025-01-28
Accepted
2025-01-28 08:00:14
Documents
13
Period of Report
2025-01-23
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K ef20042347_8k.htm   iXBRL 8-K 47360
  Complete submission text file 0001140361-25-002125.txt   185063

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA galt-20250123.xsd EX-101.SCH 4018
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20250123_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20250123_pre.xml EX-101.PRE 16068
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20042347_8k_htm.xml XML 4244
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 25560983
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)